Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy.
US court permits generic version of Teva MS drug a year sooner
Teriflunomide (Aubagio) approved for use by the NHS in Scotland and Northern Ireland
Teva announces top-line results from GALA Phase III trial evaluating a new dosage for glatiramer acetate given three times weekly for relapsing-remitting multiple sclerosis
Spin-offs: Meet the structure specialists
Daclizumab Therapy for Multiple Sclerosis.
A urinary test procedure for identification of cannabidiol in patients undergoing medical therapy with marijuana.
TGFβ Signaling Regulates the Timing of CNS Myelination by Modulating Oligodendrocyte Progenitor Cell Cycle Exit through SMAD3/4/FoxO1/Sp1.
Natalizumab treatment during pregnancy - effects on the neonatal immune system.
Sample-size calculations for short-term proof-of-concept studies of tissue protection and repair in multiple sclerosis lesions via conventional clinical imaging
Treatment Optimization in MS: Canadian MS Working Group Updated Recommendations.
More to come: humoral immune responses in MS.
New approaches in the management of multiple sclerosis.
Molecular mechanism underlying the impact of vitamin D on disease activity of MS.
Dose comparison trial of sustained-release fampridine in multiple sclerosis.
First-in-class thyrotropin-releasing hormone (TRH)-based compound binds to a pharmacologically distinct TRH receptor subtype in human brain and is effective in neurodegenerative models.
Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans.
Pharmacokinetics of CAMPATH-1H in BMT patients.
Phase 3 Study of RPC1063 in Relapsing MS
A novel oral nutraceutical formula of omega-3 and omega-6 fatty acids with vitamins (PLP10) in relapsing remitting multiple sclerosis: a randomised, double-blind, placebo-controlled proof-of-concept clinical trial.
Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone.
Interleukin-8 and RANTES levels in patients with relapsing-remitting multiple sclerosis (RR-MS) treated with cladribine.
Low Dose Naltrexone: Side Effects and Efficacy in Gastrointestinal Disorders.
Pharmacology and therapeutic potential of interferons.
Heterogeneity of serum gelatinases MMP-2 and MMP-9 isoforms and charge variants.

Pages